tradingkey.logo
tradingkey.logo
Search

Beta Bionics Inc

BBNX
Add to Watchlist
16.760USD
+0.060+0.36%
Close 07/02, 13:00ETQuotes delayed by 15 min
746.85MMarket Cap
LossP/E TTM

More Details of Beta Bionics Inc Company

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Beta Bionics Inc Info

Ticker SymbolBBNX
Company nameBeta Bionics Inc
IPO dateJan 30, 2025
CEOSaint (Sean)
Number of employees291
Security typeOrdinary Share
Fiscal year-endJan 30
Address11 Hughes
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92618
Phone19494277785
Websitehttps://www.betabionics.com
Ticker SymbolBBNX
IPO dateJan 30, 2025
CEOSaint (Sean)

Company Executives of Beta Bionics Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
95.61K
-5.86%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
23.40K
-12.01%
Mr. Adam Lezack
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
23.40K
+63.96%
Mr. Sean Saint
Mr. Sean Saint
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.67K
-297.67%
Mr. Stephen Feider
Mr. Stephen Feider
Chief Financial Officer
Chief Financial Officer
3.18K
-210.20%
Mr. Michael (Mike) Mensinger
Mr. Michael (Mike) Mensinger
Chief Product Officer
Chief Product Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
95.61K
-5.86%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
23.40K
-12.01%

FAQs

Who are the top five shareholders of Beta Bionics Inc?

The top five shareholders of Beta Bionics Inc are: Dr. Steven Russell, M.D., Ph.D.

How many institutions hold shares of Beta Bionics Inc (BBNX)?

As of 2026Q1, 264 institutions hold shares of Beta Bionics Inc, with a combined market value of approximately 49.25M, accounting for 110.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2186348.00.

What is the biggest source of revenue for Beta Bionics Inc?

In 2026Q1, the DME channel - iLet business generated the highest revenue for Beta Bionics Inc, amounting to 52.05M and accounting for 51.92% of total revenue.